A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
- Registration Number
- NCT06750276
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body
- Detailed Description
Study details include:
The study duration will be up to 63 days (9 weeks).
* 1 or 2 screening visits (up to 28 days before treatment)
* 28 days of treatment including 5 clinic visits
* Week 1: 24-hour in-clinic stay (Day 1)
* Week 2: Outpatient clinic visit (Day 7)
* Week 3: Outpatient clinic visit (Day 14)
* Week 4: Telephone visit (Day 21)
* Week 5: 24 to 48-hour in-clinic stay (Day 28)
* Week 6: Follow-up visit (Day 35) Disclosure Statement: The study consists of two cohorts, each with a parallel-group design and two arms, with participants blinded to treatment allocation.
Number of Participants:
The study will randomise approximately 36 participants in total. Cohort A: Approximately 75 participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. Cohort B: Approximately 75 participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 36
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort A AZD2389 Participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. Cohort B AZD2389 Participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo.
- Primary Outcome Measures
Name Time Method Reported quantity and severity of adverse events (AEs) following oral administration of AZD2389 Up to and including day 35 (from pre-screening to follow-up visit) Reporting frequency and severity of AEs based on qualifying symptoms, signs, abnormalities in measured values, or other diagnoses as identified by investigator
Number of participants with observed changes in blood pressure against baseline mmHg value Up to and including Day 35 (from pre-screening to follow-up visit) Assess blood pressure level (with systolic and diastolic pressure) in mmHg
Number of participants with observed changes in heart rate (BPM) against baseline value Up to and including day 35 (from pre-screening to follow-up visit) Pulse rate measured in beats per minute (BPM)
Number of participants with observed changes in Sp02 oxygen values against baseline measurement Up to and including day 35 (from pre-screening to follow-up visit) Sp02 oxygen saturations measured by percentage
Number of participants with observed changes in body temperature against baseline value Up to and including day 35 (from pre-screening to follow-up visit) Body temperature measured in degrees Celsius
Number of participants with observed changes in respiratory rate against baseline value Up to and including day 35 (from pre-screening to follow-up visit) Respiratory rate measured in respirations per minute
Number of participants with identified abnormalities in results of 12-lead safety electrocardiograms (ECG) Up to and including day 35 (from pre-screening to follow-up visit) 12-lead safety ECG (PR interval, QRS complex, ST interval, T wave)
Number of participants with changes in physical baseline values identified during physical examinations Up to and including day 35 (from pre-screening to follow-up visit) Physical examinations will include assessment of general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal (including spine and extremities) and neurological symptoms (examination of the participants' feet to observe skin integrity, circulation, and presence of any neuropathy).
Number of participants with abnormal laboratory test results detected in blood samples Up to and including day 35 (from pre-screening to follow-up visit) Hematology - Platelets (x10\^9/L) Clinical Chemistry - ALT (U/L), AST (U/L), ALP (U/L) Coagulation - INR Fibrinolysis - D-dimer (ng/mL fibrinogen-equivalent units)
Number of participants with abnormal laboratory results detected in urine samples Up to and including day 35 (from pre-screening to follow-up visit) Urinalysis - Paper chromatography
Number of participants with visible changes (against baseline observations) to the condition of abdominal organs as identified by FibroScan imaging Up to and including Day 35 (from pre-screening to follow-up visit) FibroScan (VCTE) ultrasound imaging will measure a participant's level of LSM (liver stiffness), CAP (amount of fat in the liver), and/or SSM (spleen stiffness).
- Secondary Outcome Measures
Name Time Method To evaluate the effect of AZD2389 on plasma FAP activity following oral administration of AZD2389 in participants with CLD and hepatic fibrosis From Day 1 to Day 35 Inhibition of FAP activity at Days 1, 7, 14, 28, and follow-up (calculated as change and percentage change in FAP activity against baseline) compared to placebo
Maximum Plasma Concentration (Cmax) detected in blood sample From Day 1 to Day 35 Maximum Plasma Concentration (Cmax)
Time to Maximum Concentration (Tmax) as detected in blood sample From Day 1 to Day 35 Time to Maximum Concentration (Tmax)
Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClasta) as detected in blood sample From Day 1 to Day 35 Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClasta)
Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf) as detected in blood sample From Day 1 to Day 35 Area Under the Concentration-time Curve Extrapolated to Infinity (AUCinf)
Area Under the Concentration-time Curve Over a Dosing Interval (AUCtau) as detected in blood sample From Day 1 to Day 35 Area Under the Concentration-time Curve Over a Dosing Interval (AUCtau)
Terminal Half-life (t1/2λz) as detected in blood sample From Day 1 to Day 35 Terminal Half-life (t1/2λz)
Apparent Volume of Distribution (Vz/F) as detected in blood sample From Day 1 to Day 35 Apparent Volume of Distribution (Vz/F)
Apparent Clearance (CL/F) as detected in blood sample From Day 1 to Day 35 Apparent Clearance (CL/F)
Temporal Change Parameter (TCP) as detected in blood sample From Day 1 to Day 35 Temporal Change Parameter (TCP)
Cmax Accumulation Ratio (Rac Cmax) as detected in blood sample From Day 1 to Day 35 Cmax Accumulation Ratio (Rac Cmax)
AUC Accumulation Ratio (Rac AUC) as detected in blood sample From Day 1 to Day 35 AUC Accumulation Ratio (Rac AUC)
Renal Clearance (CLR) as detected in blood sample From Day 1 to Day 35 Renal Clearance (CLR)
Amount of Drug Excreted in Urine (Ae) as detected in urine sample From Day 1 to Day 35 Amount of Drug Excreted in Urine (Ae)
Fraction of Drug Excreted in Urine (Fe) as detected in urine sample From Day 1 to Day 35 Fraction of Drug Excreted in Urine (Fe)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Research Site
🇬🇧London, United Kingdom